GT Biopharma files Form D for offering of up to $38.96 million

GT Biopharma, Inc. filed a Form D notice with the Securities and Exchange Commission for a new exempt securities offering, with a first sale date of September 14, 2026. The filing is marked as a new notice with a date of first sale of 2026-09-14.¹

The company is based in San Francisco. Its principal place of business is listed at 505 Montgomery Street, 10th Floor, San Francisco, California.¹ The offering is being made under a specific SEC exemption. GT Biopharma claimed the Rule 506(b) exemption for the offering.¹

The total offering amount and the amount already raised are disclosed in the filing. The total offering amount is $38,958,054, with $7,750,000 already sold and $31,208,054 remaining to be sold.¹ The filing states the total number of investors who have already invested in the offering is 9.¹

The securities being offered are equity. The type of securities offered is equity.¹ No sales commissions or finder's fees were reported. Sales commissions and finders' fees are both listed as $0.¹ The company also reported no proceeds directed to executive officers, directors, or promoters named in the filing. The use of proceeds for such persons is listed as $0.¹

The filing was signed by the company's chief financial officer. The Form D was signed by Alan Urban, Chief Financial Officer of GT Biopharma, Inc., on 2026-09-29.¹ GT Biopharma's related persons named in the filing include Chief Executive Officer Michael Breen and Chief Financial Officer Alan Urban¹, along with directors Charles J. Casamento, Hilary Kramer, and David C. Mun-Gavin, according to the filing's related persons section.